Abstracts tagged "Epidemiology"

Abstract Number: 0735 • ACR Convergence 2025
A Real-World Study from the Greater Paris Clinical Data Warehouse
Aïcha Kante¹, Olivier Hassanaly², Geoffroy Peyrac³, David Saadoun⁴, Cacoub Patrice⁴, Alexis REGENT⁵, Benjamin Terrier⁶, Luc Mouthon⁷, Arsène Mekinian⁸, Karim Sacré⁹, Jean-François Alexandra¹⁰, Sébastien Abad¹¹, Robin Dhote¹¹, Cécile goujard¹², Damien Sène¹³, Stéphane Mouly¹⁴, Baptiste Hervier¹⁵, Olivier Bory¹⁶, Elisabeth Aslangul¹⁶, Isabelle Mahé¹⁶, Anne Couvelard¹⁷, Yann Nguyen¹⁸, Agnès Lefort¹⁸, Sophie georgin-Lavialle¹⁹, Olivier Steichen¹⁹, Viet-Thi Tran²⁰ and Cloé Comarmond¹, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Unité de recherche clinique, AP-HP, Hôpital Saint Louis, F⁷⁵⁰¹⁰, Paris, France, Paris, France, ³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ⁵Hopital Cochin, Paris, France, ⁶Cochin Hospital, Paris, France, ⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁹Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ¹⁰Internal Medicine, Hôpital Bichat, APHP, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP); Université Paris ¹³, Sorbonne Paris Cité, Bobigny, France, Bobigny, France, ¹²Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹⁴Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁵Internal Medicine Department, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France., Paris, France, ¹⁶Department of Internal Medicine, Louis-Mourier Hospital, AP-HP, Colombes, France, Colombes, France, ¹⁷Pathology Department, Bichat and Beaujon Hospitals, AP-HP, FHU MOSAIC, Université Paris Cité, Paris, France, Paris, France, ¹⁸Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAe, Centre for Research in Epidemiology and Statistics (CRESS), Paris; and Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, AP-HP, Paris, France, Paris, France
Background/Purpose: Giant cell arteritis (GCA) relapses are frequent and often require therapeutic intensification in the form of glucocorticoids (GC) increase. GCA management has significantly evolved…
Abstract Number: 0322 • ACR Convergence 2025
Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, Shike Xu², Timothy McAlington³, John Haran⁴, Julieann Patarini⁴ and Bing Lu⁵, ¹University of Massachusetts Chan Medical School, Marlborough, NH, ²University of Connecticut Health Center, Farmington, CT, ³UMass Chan School of Medicine, Arlington, MA, ⁴UMass Chan Medical School, Worcester, MA, ⁵UConn Health Center, Newton, MA
Background/Purpose: Numerous cross-sectional and animal studies have linked an altered gut microbiome to osteoarthritis (OA). Human studies are needed to explore the association between the…
Abstract Number: 1507 • ACR Convergence 2025
Temporal Trends in the Incidence of Systemic Lupus Erythematosus (SLE) in the United States (US): Holding Steady?
Sasha Bernatsky¹, Sharon Dowell², Brittany Banbury³, Jeffrey Curtis⁴, Grace Wright⁵, Emily Holladay⁶, Amy Mudano⁷, Cristiano Moura⁸ and Gail Kerr⁹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²NEA Baptist Memorial Hospital, Jonesboro, AR, ³Mount Sinai Beth Israel, Brooklyn, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Grace C Wright MD PC, New York, NY, ⁶University of Alabama at Birmingham, Edmond, OK, ⁷Foundation for Advancing Science, Technology, Education and Research (FASTER), Birmingham, AL, ⁸Research Institute of the McGill University Health Center, Montréal, Canada, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Since SLE is associated with significant morbidity and healthcare burden, estimates of SLE incidence are needed to inform research and public health initiatives, including…
Abstract Number: 2685 • ACR Convergence 2025
Assessing for Racial/Ethnic Variability in U.S.-FRAXTM Performance Among Older Adult Women with Rheumatoid Arthritis in the United States
Rachel Elam¹, Jing Li², Angel Paul³, Emma Kersey⁴, gabriela Schmajuk⁵, William Leslie⁶ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²University of California, San Francisco, San Francisco, CA, ³University of California San Francisco, Berkeley, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁶University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Women with rheumatoid arthritis (RA) have 1.5- and 2-fold higher risk of major osteoporotic fracture (MOF: first of distal forearm, hip, humerus, or clinical…
Abstract Number: 2336 • ACR Convergence 2025
Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the “ESPALDA” Multinational Registry
Wilson bautista molano¹, Guillermo Guaracha², Fernando Sommerfleck³, Rodrigo García Salinas⁴, Julio Cesar Casasola Vargas⁵, John Londono⁶, Daniel Fernandez⁷, Diego Vila⁸, Lorena Brance⁹, Jossiel Then¹⁰, francisco Zeballos¹¹, Lysseth Macias¹², Marilu mestanza¹³, Daisy Sanchez¹⁴, lYN chincháy¹⁵, Patricia Melgarejo¹⁶, Angel Castillo¹⁷, Gimena Gomez¹⁸, Leandro ferreryra¹⁹, Dora candia²⁰, Gustavo medina²¹, Maria Erguez²², Einer Sanchez⁴ and Daniel Palleiro²³, ¹University Hospital Fundacion Santa Fe de Bogota, Bogota, Colombia, ²Instituto Nacional de Ciencias Médicas y Nutrición 'Salvador Zubirán', Ciudad de México, Mexico, Mexico, ³Sanatorio Julio Mendez, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Italiano La Plata, La Plata, Argentina, ⁵CAVJ^7111038Q⁹, MEXICO CITY, Mexico, ⁶Hospital Militar Central , Universidad de La Sabana, Colombia, Bogota, Colombia, ⁷Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia, BOGOTA, Colombia, ⁸Hospital Virgen del Carmen, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁹School of Medicine, Rosario National University, Argentina, Rosario, Argentina, ¹⁰HOMS, Santiago, Dominican Republic, ¹¹Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ¹²Consultorio sse, Hospital Metropolitano, Ecuador, Quito, Ecuador, ¹³Hospital Metropolitano, Ecuador, Quito, Ecuador, ¹⁴Sociedad Ecuatoriana de Reumatología, GUAYAS - GUAYAQUIL, Ecuador, ¹⁵Hospital Guillermo Kaelin de La Fuente, Perú, Lima, Peru, ¹⁶Instituto de Previsión Social, Villarrica, Paraguay, ¹⁷Centro médico de las Americas, Merida, Mexico, ¹⁸Sanatorio Guemes, Buenos Aires, Argentina, ¹⁹HIBA, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ²⁰Hospital Regional Primero de Octubre ISSTE, Fuerzas Armadas, México, Durango, Mexico, ²¹Clinical Hospital Buenos Aires University, Quilmes, Argentina, ²²SAR, Guayaquil, Ecuador, ²³INRU, Montevideo, Uruguay
Background/Purpose: The ESPALDA registry, developed by PANLAR, collects data from Latin America to better understand the clinical and epidemiological characteristics of patients with axial spondyloarthritis…
Abstract Number: 1911 • ACR Convergence 2025
Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort
Victoria Konzett¹, Eva Manger², Simon Reider², Johannes Griss³, Constanze Jonak³, Kastriot Kastrati⁴, Peter Mandl⁴, Gudrun Ratzinger⁵, Christina Duftner², Thomas Karonitsch⁴ and Daniel Aletaha⁶, ¹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria, ³Department of Dermatology, Medical University of Vienna, Austria, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Austria, Innsbruck, Austria, ⁶Medical University Vienna, Wien, Austria
Background/Purpose: Psoriatic arthritis (PsA) develops predominantly in patients with psoriasis (Pso). Although key drivers and predictors of disease progression have been identified in recent years,…
Abstract Number: 1886 • ACR Convergence 2025
Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: High-risk medications (HRMs) may increase the risk of adverse events such as falls and fractures, hospitalizations, hospital length of stay, and death in older…
Abstract Number: 1583 • ACR Convergence 2025
Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
Patompong Ungprasert¹ and Paul Kroner², ¹Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH, ²Riverside Health System, Newport News, VA
Background/Purpose: The inpatient epidemiology, morbidity, mortality, and healthcare expenditures of patients with systemic sclerosis (SSc) are not well-characterized. This study aims to utilize a nationwide…
Abstract Number: 1279 • ACR Convergence 2025
Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Reagan Reid¹, Huayun Hou², Isha Datar², Daniela Dominguez³, Andrea Knight⁴, Deborah Levy⁵, Lawrence Ng⁶, Zhaoyu Ding², Michael Wilson², Lauren Erdman⁷, Eleanor Pullenayegum² and Linda Hiraki⁵, ¹The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷University of Cincinnati, Cincinnati, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…
Abstract Number: 1016 • ACR Convergence 2025
Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
Ilana Usiskin¹, Lauren rusnak², Katherine Zhong³, Ying Qi⁴, Nicole Yang², Gregory McDermott⁵, Brittany Weber⁶ and Katherine Liao², ¹Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Short Hills, NJ, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Heart failure (HF) is a major cause of morbidity and mortality in rheumatoid arthritis (RA). Prior work has suggested that higher levels of inflammation…
Abstract Number: 0734 • ACR Convergence 2025
Glucocorticoid Exposure and Comorbidity Profile in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: a multi-country cohort study
Julie Mouchet¹, Lauren Revie², Tim Nguyen³, Liwei Zhao⁴, Valeria Jordan M.⁵, G S Ramakrishna⁶, Linda Grinnell-Merrick³, Atif Adam⁷ and Minouk Schoemaker⁸, ¹Novartis Pharma AG, Basel, Switzerland, ²IQVIA, EMEA, London, United Kingdom, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴IQVIA, Real World Solutions, Mölndal, Sweden, ⁵Novartis Pharmaceuticals Corporation, Tenafly, NJ, ⁶Novartis Healthcare Private Limited, Hyderabad, India, ⁷IQVIA Inc, Boston, ⁸IQVIA, Real World Solutions, Amsterdam, Netherlands
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are systemic inflammatory conditions that predominantly affect individuals ≥50 years of age. The conditions share overlapping…
Abstract Number: 0321 • ACR Convergence 2025
Per- and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, Lisa Rokoff², Bing Lu³, Timothy McAlington⁴, Charles Eaton⁵, Mary Roberts⁶, Diana Mathes⁷, Colleen Lestician⁷, Zhijin Carrie Xu⁷, Zhihua Tina Fan⁷, Shawn O'Leary⁷ and Abby Fleisch⁸, ¹University of Massachusetts Chan Medical School, Marlborough, NH, ²Center for Interdisciplinary and Population Health Research, MaineHealth Institute for Research, Westbrook, ME, ³UConn Health Center, Newton, MA, ⁴UMass Chan School of Medicine, Arlington, MA, ⁵Brown University, Pawtucket, RI, ⁶Center for Primary Care and Prevention, Kent Hospital, Pawtucket, RI, ⁷Environmental and Chemical Laboratory Services, Public Health & Environmental Laboratories, New Jersey Department of Health, Ewing, NJ, ⁸Maine Medical Center; ². Center for Interdisciplinary and Population Health Research, MaineHealth Institute for Research, Westbrook, ME
Background/Purpose: The prevalence of hand osteoarthritis (OA) has doubled in the United States over the past half century – a finding that cannot be solely…
Abstract Number: 2679 • ACR Convergence 2025
Early-Life Nutrition and Gene-Environment Interactions Influencing Juvenile Idiopathic Arthritis Risk: Results from a Pregnancy Cohort
Vilde Øverlien Dåstøl¹, Ida Henriette Caspersen², Kristine Løkås Haftorn³, Sigrid Hestetun⁴, Siri Eldevik Håberg⁵, Karen H. Costenbader⁶, Marin Strøm⁷, Sjurdur Frodi Olsen⁸, Anne Lise Brantsæter⁹, Ketil Størdal¹⁰ and Helga Sanner¹, ¹Oslo University Hospital, Oslo, Norway, ²Norwegian Institute of Public Health, Centre for Fertility and Health/Oslo University Hospital, Oslo, Norway, ³Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ⁴Oslo University Hospital, Department of Rheumatology/University of Oslo, Oslo, Norway, ⁵Norwegian Institute of Public Health, Centre for Fertility and Health/University of Bergen, Oslo, Norway, ⁶Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ⁷Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark, ⁸Statens Serum Institut,Biobank, congenital disorders, and vaccines preparedness/Harvard T.H. Chan School of Public Health, Copenhagen, Denmark, ⁹Norwegian Institute of Public Health, Department of Food Safety and Centre for Sustainable Diets, Oslo, Norway, ¹⁰Oslo University Hospital, Department of Pediatric and Adolescent Medicine/University of Oslo, Oslo, Norway
Background/Purpose: Early-life nutrition may influence the risk of immune-mediated diseases like juvenile idiopathic arthritis (JIA). The benefits of breastfeeding are well established, but findings related…
Abstract Number: 2270 • ACR Convergence 2025
ACKR1 and Leukopenia in Patients with Rheumatoid Arthritis Treated with Disease Modifying Antirheumatic Drugs
Daniela Chavez de Paz Solis¹, Puran Nepa², Laura Daniel³, Yan Guo⁴, Jonathan Mosley⁵, Michael Stein⁶ and Cecilia Chung⁴, ¹University of Maine, Caribou, ME, ²University of Miami, Research Service, Miami VA Healthcare System, Miami, FL, ³University of Miami, Nashville, TN, ⁴University of Miami, Miami, ⁵UT Southwestern Medical Center, Dallas, ⁶Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, and leflunomide arecommonly prescribed for RA treatment but carry the risk of leukopenia. The ACKR1 promoter…
Abstract Number: 1909 • ACR Convergence 2025
Trends of venous thromboembolism after total joint replacement in the United Kingdom after the introduction of NICE guidelines.
Subhashisa Swain¹, Nadja Leith², Sarah Brown², Cynthia Wright Drakesmith², Jonathan Rees³, Clare Bankhead⁴ and John Powell⁴, ¹Keele University, University of Oxford, Keele, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³NDORMS, University of Oxford, Oxford, United Kingdom, ⁴NDPCHS, University of Oxford, Oxford, United Kingdom
Background/Purpose: Joint replacement (JR) surgery is one of the preferred management for end-stage arthritis. Venous Thromboembolism (VTE) is one of the major post-surgical complications after…

« Previous Page
1
…
6
7
8
9
10
…
55
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].